Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharmacol Res ; 77: 11-21, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24004656

RESUMEN

Neuroblastoma malignant cell growth is dependent on their undifferentiated status. Arsenic trioxide (As2O3) induces neuroblastoma cell differentiation in vitro, but its mechanisms still remains unknown. We used three human neuroblastoma cell lines (SH-SY5Y, IGR-N-91, LAN-1) that differ from their MYCN and p53 status to explore the intracellular events activated by As2O3 and involved in neurite outgrowth, a morphological marker of differentiation. As2O3 (2µM) induced neurite outgrowth in all cell lines, which was dependent on ERK activation but independent on MYCN status. This process was induced either by a sustained (3 days) or a transient (2h) incubation with As2O3, indicating that very early events trigger the induction of differentiation. In parallel, As2O3 induced a rapid assembly of promyelocytic leukemia nuclear bodies (PML-NB) in an ERK-dependent manner. In conclusion, mechanisms leading to neuroblastoma cell differentiation in response to As2O3 appear to involve the ERK pathway activation and PML-NB formation, which are observed in response to other differentiating molecules such as retinoic acid derivates. This open new perspectives based on the use of treatment combinations to potentiate the differentiating effects of each drug alone and reduce their adverse side effects.


Asunto(s)
Antineoplásicos/farmacología , Arsenicales/farmacología , Diferenciación Celular/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Cuerpos de Inclusión Intranucleares/metabolismo , Leucemia Promielocítica Aguda/patología , Neuroblastoma/patología , Proteínas Nucleares/metabolismo , Óxidos/farmacología , Factores de Transcripción/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Trióxido de Arsénico , Arsenicales/uso terapéutico , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Activación Enzimática/efectos de los fármacos , Humanos , Cuerpos de Inclusión Intranucleares/efectos de los fármacos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Leucemia Promielocítica Aguda/metabolismo , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteína Proto-Oncogénica N-Myc , Neuritas/efectos de los fármacos , Neuritas/ultraestructura , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/metabolismo , Proteínas Oncogénicas/metabolismo , Óxidos/uso terapéutico , Proteína de la Leucemia Promielocítica
2.
J Mol Neurosci ; 36(1-3): 8-15, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18574733

RESUMEN

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide that belongs to the secretin/glucagon/vasoactive intestinal polypeptide superfamily. The PACAPergic system is actively expressed in the developing cerebellum of mammals. In particular, PACAP receptors are expressed by granule cell precursors suggesting a role of the peptide in neurogenesis of this cell type. Consistent with this hypothesis, several studies reported antiapoptotic effects of PACAP in the developing cerebellum. On the other hand, the sphingomyelin metabolites ceramides are recognized as important signaling molecules that play pivotal roles during neuronal development. Ceramides, which production can be induced by death factors such as FasL or TNFalpha, are involved in the control of cell survival during brain development through activation of caspase-dependent mechanisms. The present review focuses on the interactions between PACAP and ceramides in the control of granule cell survival and on the transduction mechanisms associated with the anti- and proapoptotic effects of PACAP and ceramides, respectively.


Asunto(s)
Apoptosis/fisiología , Ceramidas/metabolismo , Cerebelo , Neuronas/fisiología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/metabolismo , Animales , Ceramidas/química , Cerebelo/citología , Cerebelo/crecimiento & desarrollo , Estructura Molecular , Neuronas/citología , Sistemas de Mensajero Secundario/fisiología
3.
Cell Death Differ ; 15(6): 1042-53, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18323863

RESUMEN

Transplantation of neuronal precursor cells (NPCs) into the central nervous system could represent a powerful therapeutical tool against neurodegenerative diseases. Unfortunately, numerous NPCs die shortly after transplantation, predominantly due to caspase-dependent apoptosis. Using a culture of cerebellar neuronal precursors, we have previously demonstrated protective effect of the neuropeptide PACAP, which suppresses ceramide-induced apoptosis by blockade of the mitochondrial apoptotic pathway. The main objective of this study was to determine whether Bax repression can promote survival of NPCs allotransplanted into a host animal. In vivo and ex vivo experiments revealed that C2-ceramide increases Bax expression, while PACAP reverses this effect. In vitro tests using cerebellar NPCs demonstrated that the Bax-specific small interfering RNA (siRNA) could reduce their death and caspase-3 cleavage within the first 24 h. BrdU-labelled NPCs were subjected to transfection procedure with or without siRNA introduction before using for in vivo transplantation. Twenty-four hours after, the allografted NPCs containing siRNA showed significantly reduced level of caspase-3 cleavage, and the volume of their implants was almost twofold higher than in the case of empty-transfected precursors. These data evidence an important role of Bax in life/death decision of grafted NPCs and suggest that RNA interference strategy may be applicable for maintaining NPCs survival within the critical first hours after their transplantation.


Asunto(s)
Inhibidores de Caspasas , Cerebelo/citología , Neuronas/citología , Trasplante de Células Madre , Células Madre/metabolismo , Proteína X Asociada a bcl-2/antagonistas & inhibidores , Animales , Caspasa 3/metabolismo , Supervivencia Celular , Células Cultivadas , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/farmacología , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Ratas , Ratas Wistar , Esfingosina/análogos & derivados , Esfingosina/farmacología , Células Madre/efectos de los fármacos , Células Madre/enzimología , Trasplante Homólogo , Proteína X Asociada a bcl-2/genética , Proteína X Asociada a bcl-2/metabolismo
4.
J Neuroendocrinol ; 19(5): 321-7, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17425606

RESUMEN

Pituitary adenylate cyclase-activating polypeptide (PACAP) was originally isolated from ovine hypothalamus on the basis of its hypophysiotrophic activity. It has subsequently been shown that PACAP and its receptors are widely distributed in the central nervous system of adult mammals, indicating that PACAP may act as a neurotransmitter and/or neuromodulator. It has also been found that PACAP and its receptors are expressed in germinative neuroepithelia, suggesting that PACAP could be involved in neurogenesis. There is now compelling evidence that PACAP exerts neurotrophic activities in the developing cerebellum and in embryonic stem (ES) cells. In particular, the presence of PACAP receptors has been demonstrated in the granule layer of the immature cerebellar cortex, and PACAP has been shown to promote survival, inhibit migration and activate neurite outgrowth of granule cell precursors. In cerebellar neuroblasts, PACAP is a potent inhibitor of the mitochondrial apoptotic pathway through activation of the MAPkinase extracellular regulated kinase. ES cells and embryoid bodies (EB) also express PACAP receptors and PACAP facilitates neuronal orientation and induces the appearance of an electrophysiological activity. Taken together, the anti-apoptotic and pro-differentiating effects of PACAP characterised in cerebellar neuroblasts as well as ES and EB cells indicate that PACAP acts not only as a neurohormone and a neurotransmitter, but also as a growth factor.


Asunto(s)
Apoptosis/fisiología , Diferenciación Celular/fisiología , Cerebelo/citología , Células Madre Embrionarias/citología , Neuronas/citología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/fisiología , Animales , Cerebelo/crecimiento & desarrollo , Cerebelo/fisiología , Células Madre Embrionarias/fisiología , Regulación del Desarrollo de la Expresión Génica , Humanos , Factor de Crecimiento Nervioso/fisiología , Neuronas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...